BACKGROUND: Endothelial dysfunction, common to diabetes and cardiovascular diseases, is an early step in the development of atherosclerosis and diabetic angiopathies. Deficiencies of taurine have been related to diabetes and cardiovascular diseases. AIMS OF THE STUDY: We investigated whether taurine provides protective action against endothelial dysfunction induced by hyperglycemia and/or oxidized low density lipoproteins (oxLDL). METHODS: Quiescent human umbilical cord venous endothelial cells were exposed for 20 h to high glucose (35 mM) and/or oxLDL (60 microg/ml) alone and in presence of taurine (0.5-2.5 mg/ml). Apoptosis, caspase-3 activity, soluble(s) and cell surface expressions of vascular cellular (VCAM-1) and intercellular (ICAM-1) adhesion molecules were determined. Results are given as a percentage of the low glucose medium control. Apoptosis, VCAM-1 and ICAM-1 expressions were related to cell number. RESULTS: Hyperglycemia increased apoptosis to 162.5 +/- 19.2%, caspase-3 activity to 153.2 +/- 10.3%, cell-surface expression of VCAM-1 to 125.1 +/- 5.8%, the expression of ICAM-1 to 123.7 +/- 2.8% and sICAM-1 to 146.5 +/- 7.9%. Taurine (0.5-2.5 mg/ml) restored apoptosis, caspase-3 activity and expressions of VCAM-1 and ICAM-1. OxLDL (60 microg/ml) increased apoptosis to 114.8 +/- 3.1%; taurine (2.5 mg/ml) reduced this apoptosis to 40.5 +/- 4.1%. The combination of hyperglycemia and oxLDL increased apoptosis to 211.7 +/- 11.6%. This increase was normalized by taurine (2.5 mg/ml) to 97.9 +/- 12.8%. CONCLUSION: Taurine protects HUVECs from endothelial dysfunction induced by hyperglycemia through down-regulation of apoptosis and adhesion molecules. Counteracting the combination of oxLDL and hyperglycemia requires pharmacological concentrations of taurine.
BACKGROUND:Endothelial dysfunction, common to diabetes and cardiovascular diseases, is an early step in the development of atherosclerosis and diabetic angiopathies. Deficiencies of taurine have been related to diabetes and cardiovascular diseases. AIMS OF THE STUDY: We investigated whether taurine provides protective action against endothelial dysfunction induced by hyperglycemia and/or oxidized low density lipoproteins (oxLDL). METHODS: Quiescent human umbilical cord venous endothelial cells were exposed for 20 h to high glucose (35 mM) and/or oxLDL (60 microg/ml) alone and in presence of taurine (0.5-2.5 mg/ml). Apoptosis, caspase-3 activity, soluble(s) and cell surface expressions of vascular cellular (VCAM-1) and intercellular (ICAM-1) adhesion molecules were determined. Results are given as a percentage of the low glucose medium control. Apoptosis, VCAM-1 and ICAM-1 expressions were related to cell number. RESULTS:Hyperglycemia increased apoptosis to 162.5 +/- 19.2%, caspase-3 activity to 153.2 +/- 10.3%, cell-surface expression of VCAM-1 to 125.1 +/- 5.8%, the expression of ICAM-1 to 123.7 +/- 2.8% and sICAM-1 to 146.5 +/- 7.9%. Taurine (0.5-2.5 mg/ml) restored apoptosis, caspase-3 activity and expressions of VCAM-1 and ICAM-1. OxLDL (60 microg/ml) increased apoptosis to 114.8 +/- 3.1%; taurine (2.5 mg/ml) reduced this apoptosis to 40.5 +/- 4.1%. The combination of hyperglycemia and oxLDL increased apoptosis to 211.7 +/- 11.6%. This increase was normalized by taurine (2.5 mg/ml) to 97.9 +/- 12.8%. CONCLUSION:Taurine protects HUVECs from endothelial dysfunction induced by hyperglycemia through down-regulation of apoptosis and adhesion molecules. Counteracting the combination of oxLDL and hyperglycemia requires pharmacological concentrations of taurine.
Authors: X L Du; G Z Sui; K Stockklauser-Färber; J Weiss; S Zink; B Schwippert; Q X Wu; D Tschöpe; P Rösen Journal: Diabetologia Date: 1998-03 Impact factor: 10.122
Authors: C Claise; M Edeas; N Chaouchi; J Chalas; L Capel; S Kalimouttou; A Vazquez; A Lindenbaum Journal: Atherosclerosis Date: 1999-11-01 Impact factor: 5.162
Authors: T Heitzer; S Ylä-Herttuala; J Luoma; S Kurz; T Münzel; H Just; M Olschewski; H Drexler Journal: Circulation Date: 1996-04-01 Impact factor: 29.690
Authors: F Franconi; F Bennardini; A Mattana; M Miceli; M Ciuti; M Mian; A Gironi; R Anichini; G Seghieri Journal: Am J Clin Nutr Date: 1995-05 Impact factor: 7.045
Authors: Andrey G Taranukhin; Elena Y Taranukhina; Pirjo Saransaari; Irina M Podkletnova; Markku Pelto-Huikko; Simo S Oja Journal: J Biomed Sci Date: 2010-08-24 Impact factor: 8.410
Authors: Stella Baliou; Maria Adamaki; Petros Ioannou; Aglaia Pappa; Mihalis I Panayiotidis; Demetrios A Spandidos; Ioannis Christodoulou; Anthony M Kyriakopoulos; Vassilis Zoumpourlis Journal: Mol Med Rep Date: 2021-06-29 Impact factor: 2.952